Boston Scientific (NYSE:BSX) said today that it won pre-market approval from the FDA for the Vici peripheral venous stent it acquired when it bought Veniti last year.

Marlborough, Mass.-based Boston Scientific said the FDA approved Vici for treating iliofemoral venous obstructive disease. The company inked a deal worth up to $160 million last August to acquire the 75% of Veniti it didn’t already own, including $52 million in potential milestones dependent on FDA approval. Veniti won CE Mark approval for the Vici stent in 2013.

“The FDA approval of the Vici venous stent system is the latest example of our commitment to building the most comprehensive portfolio of technologies specifically developed to meet the needs of physicians treating both chronic and acute venous disease,” peripheral interventions president Jeff Mirviss said in prepared remarks. “We are pleased to provide this differentiated stent system to U.S. patients suffering from debilitating deep venous disease.”

“For those suffering from venous obstructive disease, their quality of life may suffer without treatment options optimized for the disease,” added Dr. Mahmood Razavi or Orange, Calif.’s St. Joseph Hospital. “With the approval of the VICI stent, clinicians now have access to a stent that was purposely developed and engineered to resist the vessel compression and anatomical tortuosity commonly found within the iliofemoral venous system, enabling our ability to deliver best outcomes for our patients.”